‘Next-Generation Therapeutic Antibody Revenues to Reach $2.3bn in 2015′ Says New Report by visiongain

LONDON, November 10, 2011 -

www.visiongain.com/Report/712/Next-Generation-Antibody-Therapies-Pipeline-and-Market-2011-2021

A new report by visiongain, a London-based business information company, predicts that the antibody therapeutics sector will be revitalised by the approval of next-generation products this decade. Overall next-generation therapeutic antibody revenues will reach $2.3bn in 2015. That analysis appears in Next-Generation Antibody Therapies: Pipeline and Market 2011-2021, published in November 2011.

Visiongain’s report identifies seven new classes of antibody products that will have marketed products by 2016. Engineered monoclonal antibodies with improved glycosylation and enhanced effector functions are already reaching the market. So are antibody-drug conjugates (ADCs) and bispecific antibodies, sectors that have gained their first approvals in the past two years. Dynamic R&D pipelines underpin these classes of antibodies. They will be joined in the next five years by third-generation antibody fragments, alternative binding proteins and new-generation recombinant polyclonal antibodies. Biosimilar antibodies will also enter the established markets as regulatory authorities clear an approval pathway for them.

Dr James Evans, pharmaceutical industry analyst, said: “The antibodies sector has never stood still, but right now it’s on the verge of several potentially significant breakthroughs. ADCs, bispecifics and other technologies will increase antibody potency to new levels. New miniaturised fragments may be able to hit clinical targets inaccessible to full-size existing products. Alternative binding proteins and recombinant polyclonal antibodies could challenge the existing monoclonal immunoglobulin paradigm. Also, biosimilar antibodies are coming, and will be important in the developed national markets, where demand for them is high.”  

The overall antibody-based drug market will grow steadily this decade, the report shows. The next-generation share of therapeutic antibody revenues will increase as those newer products outstrip the existing market leaders for revenue growth. With higher potency, broader targeting, more-convenient delivery systems, and lower costs among the benefits offered by next-generation antibody products, their commercial impact will be significant. This new study adds to visiongain’s range of analytical reports covering fast-developing markets in the pharmaceutical industry.

To view sample pages please click on: www.visiongain.com/Report/712/Next-Generation-Antibody-Therapies-Pipeline-and-Market-2011-2021

Table of Contents

1. Executive Summary
1.1 Next-Generation Antibodies: Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods

2. Antibody Therapeutics: Scientific and Clinical Overview, 2011
2.1 Antibodies and the Immune System
2.2 How Antibodies Work
2.3 Structure of Antibodies
2.3.1 The Fab Region
2.3.2 The Fc Region
2.4 Brief History of Antibody Discovery and Innovation
2.5 Types of Therapeutic Antibody
2.5.1 Polyclonal Antibodies
2.5.2 Monoclonal Antibodies
2.5.3 Murine Monoclonal Antibodies
2.5.4 Chimeric and Humanised Monoclonal Antibodies
2.5.5 Fully Human Monoclonal Antibodies
2.5.6 Fab Fragments
2.5.7 Fusion Proteins
2.6 Currently-Approved Monoclonal Antibody Therapies
2.7 Potential Next-Generation Antibody Therapeutics

3. Antibody Therapeutics: Pipeline and Market Overview, 2011-2021
3.1 Antibody Therapeutics: Market Forecast, 2011-2021
3.3.1 Next-Generation Products will Increase Their Market Share
3.2 Antibody Therapeutics Market, 2011-2021: Pipeline Overview
3.3 Leading Players in the Antibody Field, 2011-2021
3.4 Leading National Antibody Markets
3.5 Next-Generation Therapeutic Antibody Technologies: SWOT Analysis
3.5.1 Strengths
3.5.2 Weaknesses
3.5.3 Opportunities
3.5.4 Threats

4. Engineered Antibodies Market, 2011-2021
4.1 Engineered Antibodies: Market Forecast, 2011-2021
4.2 Engineered Antibodies: Overview of the Field in 2011
4.2.1 The Major Fc Engineering Platforms
4.2.2 New Expression Systems, Purification Systems, and Other Production Improvements
4.3 Engineered Antibodies: Products and Pipeline, 2011
4.3.1 Afutuzumab and Other GlycoMAB-Engineered Products (Roche)
4.3.2 KW0761 and Other Potelligent Products (Kyowa Hakko Kirin)
4.3.3 XmAb (Xencor)
4.3.4 MGAH22 and MGA271 (Macrogenics)
4.3.5 AME-133v (Mentrik Biotech)
4.3.6 LFB-R603 (LFB)
4.4 Engineered Antibodies: SWOT Analysis
4.4.1 Strengths
4.4.2 Weaknesses
4.4.3 Opportunities
4.4.4 Threats

5. Antibody-Drug Conjugates Market 2011-2021
5.1 Antibody-Drug Conjugates: Market Forecast, 2011-2021
5.2 Antibody-Drug Conjugates: Overview of the Field in 2011
5.2.1 Existing Antibody-Drug Conjugate Products
5.3 Antibody-Drug Conjugates Pipeline, 2011
5.3.1 Trastuzumab DM-1(Roche)
5.3.2 Roche’s Other ADC Collaborations (Roche/ Seattle Genetics)
5.3.3 CMC-544 (Pfizer)
5.3.4 IMGN901 (ImmunoGen)
5.3.5 BT-062 (Biotest)
5.3.6 CDX-011 and CDX-014 (Celldex)
5.3.7 BIIB015 (Biogen Idec)
5.3.8 SAR3419 and SAR566658 (Sanofi)
5.3.9 hLL1-Dox and Others (Immunomedics)
5.3.10 MDX-1203 (Bristol-Myers Squibb)
5.3.11 SGN-75 (Seattle Genetics)
5.3.12 AGS-5ME and Others (Astellas/ Agensys/ Seattle Genetics)
5.3.13 BAY 79-4620 and BAY 94-9343 (Bayer Schering/ Seattle Genetics / ImmunoGen)
5.3.14 PSMA ADC (Progenics Pharmaceuticals/ Seattle Genetics)
5.3.15 HuMax ADCs (Genmab/ Seattle Genetics)
5.3.16 Antibody-Radioisotope and Other Immunoconjugate Formats (Various)
5.4 Antibody-Drug Conjugates: SWOT Analysis
5.4.1 Strengths
5.4.2 Weaknesses
5.4.3 Opportunities
5.4.4 Threats

6. Bispecific Antibodies Market 2011-2021
6.1 Bispecific Antibodies: Market Forecast, 2011-2021
6.2 Bispecific Antibodies: Overview of the Field in 2011
6.3 Bispecific Antibodies: Pipeline, 2011
6.3.1 Blinatumumab (Micromet)
6.3.2 Other BiTE Products in Development
6.3.3 Rexomun and FBT A05 (Fresenius)
6.3.4 MM-111 (Merrimack)
6.3.5 ImmTAC System (Immunocore)
6.3.6 Tandab (Affimed)
6.3.7 DART Platform (MacroGenics)
6.3.8 CrossMAbs, LUZ-Y and Two-in-One Antibodies (Roche)
6.3.9 Electrostatic Matching (Amgen)
6.3.10 Duobodies (Genmab)
6.3.11 SEED Bodies (Merck Serono)
6.3.12 CovX-Bodies (Pfizer)
6.3.13 TCR-Like Antibodies (ReceptorLogic)
6.3.14 COMBODY (Epigen Biotech)
6.3.15 DVD-Ig (Abbott)
6.3.16 IgG-Like Bispecific (Eli Lilly)
6.3.17 BsAb (Bristol-Myers Squibb)
6.3.18 Hercules (Biogen Idec)
6.3.19 Scorpion (Emergent BioSolutions)
6.3.20 Tribody (Biotecnol)
6.3.21 Dock-and-Lock (ImmunoMedics)
6.3.22 Immunocytokines (ImmunGene)
6.3.23 COBRA (Merus)
6.4 Bispecific Antibodies: SWOT Analysis
6.4.1 Strengths
6.4.2 Weaknesses
6.4.3 Opportunities
6.4.4 Threats

7. Antibody Fragments Market 2011-2021
7.1 Antibody Fragments: Market Forecast, 2011-2021
7.2 Antibody Fragments: Overview of the Field in 2011
7.3 Antibody Fragments: Pipeline, 2011
7.3.1 CEP-37247 (Cephalon)
7.3.2 GSK1827771 and Others (GlaxoSmithKline)
7.3.3 Nanobodies (Ablynx)
7.3.4 ESBA105 (ESBATech)
7.3.5 Unibodies (GenMab)
7.3.6 IgNARs (Pfizer)
7.4 Antibody Fragments: SWOT Analysis, 2011
7.4.1 Strengths
7.4.2 Weaknesses
7.4.3 Opportunities
7.4.4 Threats

8. Alternative Binding Proteins Market 2011-2021
8.1 Alternative Binding Proteins: Market Forecast, 2011-2021
8.2 Alternative Binding Proteins: Overview of the Field in 2011
8.3 Alternative Binding Proteins: Pipeline, 2011
8.3.1 Adnectins (Adnexus)
8.3.2 DARPins (Molecular Partners)
8.3.3 Anticalins (Pieris)
8.3.4 Affibodies (Affibody)
8.3.5 Avimers (Amgen)
8.3.6 Transbodies (Pfizer)
8.3.7 Fynomers (Covagen)
8.3.8 Affilins (Scil Proteins)
8.3.9 Evibodies (Arana Therapeutics)
8.3.10 C-Type Lectins (Borean Pharma)
8.4 Alternative Binding Proteins: SWOT Analysis, 2011
8.4.1 Strengths
8.4.2 Weaknesses
8.4.3 Opportunities
8.4.4 Threats

9. Polyclonal Antibodies Market 2011-2021
9.1 Polyclonal Antibodies: Market Forecast, 2011-2021
9.2 Polyclonal Antibodies: Overview of the Field in 2011
9.3 Polyclonal Antibodies: Pipeline, 2011
9.3.1 Symphogen Polyclonal Antibodies Platform
9.3.2 Merus HYDRA Polyclonal Antibodies Platform
9.4 Polyclonal Antibodies: SWOT Analysis, 2011
9.4.1 Strengths
9.4.2 Weaknesses
9.4.3 Opportunities
9.4.4 Threats

10. Biosimilar Antibodies Market 2011-2021
10.1 Biosimilar Antibodies: Market Forecast, 2011-2021
10.2 Overview of Biosimilar Antibodies
10.3 Biosimilar Antibodies: Prospects in 2011
10.3.1 Biosimilar Antibody Regulatory Guidance in Europe
10.4 Biosimilar Antibodies: SWOT Analysis, 2011
10.4.1 Strengths
10.4.2 Weaknesses
10.4.3 Opportunities
10.4.4 Threats

11. Research Interviews
11.1 Interview with Dr Jason Kantor
11.1.1 On Progress in Antibody-Drug Conjugates
11.1.2 On Pharma Strategies for Next-Generation Antibody Technologies
11.1.3 On Competition between Next-Generation Sectors
11.1.4 On Engineered Antibodies
11.1.5 On Biosimilars
11.1.6 On Next-Generation Antibodies and Personalised Medicine
11.2 Interview with Professor Arne Skerra
11.2.1 On the Benefits of Non-Immunoglobulin Binding Proteins
11.2.2 On the Alternative Binding Proteins Pipeline
11.2.3 On Big Pharma Buyouts and Business Drivers in the Sector
11.2.4 On Antibody Fragments Compared to Alternative Binding Proteins
11.2.5 On Pieris’ Lipocalin Scaffolds and Lead Candidate Angiocal
11.2.6 On Immunogenicity and Plasma Half-Life

12. Conclusions
12.1 A New Generation of Antibody Products is Emerging
12.2 Some Next-Generation Antibodies are Already Here
12.3 Other Innovative Platforms are about to Achieve Market Breakthrough
12.4 Next-Generation Products Will Have Important Consequences for Other Antibodies

Companies Listed

Abbott Laboratories
Ablynx
Alexion Pharmaceuticals
Amgen
Arana Therapeutics
Astellas Pharma
AstraZeneca
Affibody
Affimed Therapeutics
American Society of Clinical Oncology
Applied Molecular Evolution
Bayer Healthcare
Bayer Schering
BayTech Venture Capital
BioCon
Biogen Idec
Biolex Therapeutics
BioTech Pharma
Biotecnol
Biotest Pharmaceuticals
BioWa
Boehringer Ingelheim
Borean Pharma
Bradmer Pharmaceuticals
Bristol-Myers Squibb
Cancer Research Technology
Celldex Therapeutics
Celltech
Cell Therapeutics
Cephalon
Cevec Pharmaceuticals
Chengdu Hoist Biotech
Corixa Corporation
Crucell
Covagen
Daiichi Sankyo
Delenex Therapeutics
Diversys
Domantis
Dresden University of Technology
Dr. Reddy’s Laboratories
Elan Pharmaceuticals
Eli Lilly
Emergent BioSolutions
Epigen Biotech
ESBATech
EuroFarma
European Medicines Agency (EMEA/EMA)
Food and Drug Administration (US FDA)
Forbion Capital
Fresenius
Genentech
Genmab
Gilde Healthcare Partners
GlaxoSmithKline (GSK)
Global Life Science Ventures
GlycArt
GTV Biotherapeutics
Haptogen
Human Genome Sciences
ImmunGene
Immunocore
ImmunoGen
Immunomedics
Isu Abxis
Johnson & Johnson
Kyowa Hakko Kirin
Laboratoires Français de Fractionnement et des Biotechnologies (LFB)
Ludwig Institute for Cancer Research
Mabgene
Macrogenics
Medarex
MedImmune
Meiji Seika Pharma
Memorial Sloan-Kettering Cancer Center
Mentrik Biotech
Merck & Co.
Merck KGaA
Merck Serono
Merrimack Pharmaceuticals
Merus Biopharmaceuticals
Micromet
Molecular Partners
MorphoSys
Novartis
OrbiMed Advisors
Oslo University Hospital
Oxford BioMedica
Peptech Corporation
Percivia
Pfizer
Pharming Healthcare
Pieris
Progenics Pharmaceuticals
RBC Capital Markets
ReceptorLogic
Regeneron Pharmaceuticals
Roche
Roslin Institute
Sanofi
Scil Proteins
SeaGen Secure
Seattle Genetics
Soroka University Medical Centre
Spectrum Pharmaceuticals
Sutro Biopharma
Swiss Federal Institute of Technology
Symphogen
Takeda Pharmaceutical Company
Technical University of Munich
Teva Pharmaceutical Industries
Tufts Centre for Drug Discovery
UCB
University of Aberdeen
University of Oxford
Viragen
Wacker Biosolutions
Wyeth
Xencor 

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

Notes for Editors

For an exec summary, or if you are interested in a more detailed overview of this report, please contact Sara Peerun

Email : sara.peerun@visiongainglobal.com
Tel: +44(0)207-3366100

Web: www.visiongain.com

.